Literature DB >> 26557822

Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.

Amelie Schramm1, Nikolaus De Gregorio1, Peter Widschwendter1, Visnja Fink1, Jens Huober1.   

Abstract

About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse prognosis and increased risk of recurrent disease. Trastuzumab, the first anti-HER2 antibody, revolutionized the systemic therapy options in HER2-positive breast cancer and initiated several targeted therapies and more personalized treatment strategies. Over the years, multiple HER2-targeting drugs stepped into clinical practice, for the curative as well as the metastatic situation. This review summarizes the targeted treatment options in HER2-positive breast cancer and their current impact in the clinical routine. Results of the most outstanding trials in HER2-targeted therapies and important ongoing trials are subsequently described for an up-to-date overview.

Entities:  

Keywords:  Dual HER2 blockade; HER2-positive breast cancer; Targeted therapies

Year:  2015        PMID： 26557822      PMCID： PMC4569208          DOI： 10.1159/000431029

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  38 in total

Review 1.  Role of HER2 gene overexpression in breast carcinoma.

Authors:  S Ménard; E Tagliabue; M Campiglio; S M Pupa
Journal:  J Cell Physiol       Date:  2000-02       Impact factor: 6.384

2.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

3.  Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

Authors:  Edith A Perez; Vera J Suman; Nancy E Davidson; Julie R Gralow; Peter A Kaufman; Daniel W Visscher; Beiyun Chen; James N Ingle; Shaker R Dakhil; Joanne Zujewski; Alvaro Moreno-Aspitia; Thomas M Pisansky; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

4.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

5.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

6.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

Authors:  Rita Nahta; Mien-Chie Hung; Francisco J Esteva
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

Review 10.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30
View more
  9 in total

1.  Progress in breast cancer-can we do better?

Authors:  S F Dent
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 2.  A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping.

Authors:  Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Vision Res       Date:  2017-08-02       Impact factor: 1.886

3.  Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Authors:  Christin Gasch; Theresa Oldopp; Oliver Mauermann; Tobias M Gorges; Antje Andreas; Cornelia Coith; Volkmar Müller; Tanja Fehm; Wolfgang Janni; Klaus Pantel; Sabine Riethdorf
Journal:  Mol Oncol       Date:  2016-07-22       Impact factor: 6.603

4.  HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.

Authors:  Courtney A Bartel; Mark W Jackson
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

5.  Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.

Authors:  Jiangsong Jiang; Nishant Mohan; Yukinori Endo; Yi Shen; Wen Jin Wu
Journal:  Oncotarget       Date:  2017-12-21

6.  Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.

Authors:  Wesam Abdel-Razaq; Mohammed Alzahrani; Majed Al Yami; Faisal Almugibl; Mohammed Almotham; Razan Alregaibah
Journal:  J Pharm Bioallied Sci       Date:  2019 Oct-Dec

7.  Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report.

Authors:  Cristiana Bergamini; Stefano Cavalieri; Giuseppe Sanguineti; Alessia Farneti; Lisa Licitra
Journal:  Oxf Med Case Reports       Date:  2019-10-31

8.  Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.

Authors:  Yunli Tong; Yuting Liu; Hongming Zheng; Liang Zheng; Wenqin Liu; Jinjun Wu; Rilan Ou; Guiyu Zhang; Fangyuan Li; Ming Hu; Zhongqiu Liu; Linlin Lu
Journal:  Oncotarget       Date:  2016-05-24

9.  Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway.

Authors:  Tao Wang; Jian Wang; Wei Ren; Zhu-Long Liu; Yu-Feng Cheng; Xiao-Mei Zhang
Journal:  Thorac Cancer       Date:  2020-07-12       Impact factor: 3.500
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.